Category

NASDAQ

The tech trade is back, driven by A.I. craze and prospect of a less aggressive Fed NASDAQ

The tech trade is back, driven by A.I. craze and prospect of a less aggressive Fed

Jen-Hsun Huang, president and chief executive officer of Nvidia Corp., speaks during the company's event at Mobile World Congress Americas in Los Angeles, California, U.S., on Monday, Oct. 21, 2019. Patrick T. Fallon | Bloomberg | Getty Images Forget about the debt ceiling. Tech investors are in buy mode. The…
bubmag
May 26, 2023
Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules NASDAQ

Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / May 26, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announced registered direct offering of an aggregate of…
bubmag
May 26, 2023
Trump’s Truth Social Faces More Trouble: SEC Calls SPAC’s Financial Statements Unreliable As Stock Faces Delisting NASDAQ

Trump’s Truth Social Faces More Trouble: SEC Calls SPAC’s Financial Statements Unreliable As Stock Faces Delisting

Topline Digital World Acquisition Corp., which plans to merge with the parent company of Donald Trump’s Truth Social platform, reported it made accounting errors in its last financial report, adding to financial reporting issues that have threatened to delist the company from Nasdaq, on top of two investigations that have…
bubmag
May 25, 2023
Bitfarms Announces Results of Annual General and Special Meeting of Shareholders NASDAQ

Bitfarms Announces Results of Annual General and Special Meeting of Shareholders

Author of the article: Published May 24, 2023  •  8 minute read This news release constitutes a “designated news release” for purposes of the Company’s prospectus supplement dated August 16, 2021, to its short form base shelf prospectus dated August 12, 2021. TORONTO, Ontario and BROSSARD, Québec, May 24, 2023…
bubmag
May 24, 2023
Canaccord Genuity Maintains Intercept Pharmaceuticals (ICPT) Hold Recommendation NASDAQ

Canaccord Genuity Maintains Intercept Pharmaceuticals (ICPT) Hold Recommendation

Fintel reports that on May 23, 2023, Canaccord Genuity maintained coverage of Intercept Pharmaceuticals (NASDAQ:ICPT) with a Hold recommendation. Analyst Price Forecast Suggests 160.70% Upside As of May 11, 2023, the average one-year price target for Intercept Pharmaceuticals is 24.84. The forecasts range from a low of 12.12 to a…
bubmag
May 23, 2023